Perihype Tablet contains Perindopril Erbumine 4 mg, an angiotensin-converting enzyme (ACE) inhibitor used primarily to manage hypertension (high blood pressure) and certain types of heart conditions. Perindopril works by inhibiting the enzyme that converts angiotensin I to angiotensin II—a powerful vasoconstrictor. By reducing angiotensin II levels, Perindopril relaxes blood vessels, lowers blood pressure, and improves blood flow, thereby reducing the workload on the heart. It also helps protect kidney function in hypertensive and diabetic patients and is widely used to manage stable coronary artery disease and chronic heart failure. The 4 mg strength is commonly used either alone or as part of a stepwise titration strategy in monotherapy or combination therapy. Perihype is recognized for its cardiovascular protective benefits, once-daily dosing, and good tolerability in long-term treatment regimens.
Common side effects of Perihype Tablet include dizziness, fatigue, headache, and a dry or persistent cough—an effect commonly associated with ACE inhibitors. Other possible adverse effects include hypotension (especially after the first dose), gastrointestinal upset, rash, and taste disturbances. In rare cases, it may cause angioedema (swelling of the face, lips, or throat), elevated potassium levels, or kidney function impairment. Periodic monitoring of blood pressure, renal function, and electrolytes is advised during therapy.
Perihype Tablet is indicated for the treatment of essential hypertension in adults. It is also used in the management of heart failure (especially in patients with symptomatic left ventricular dysfunction) and in reducing the risk of cardiovascular events in patients with stable coronary artery disease. It may be prescribed as monotherapy or alongside other antihypertensive agents such as diuretics or calcium channel blockers.
Perihype Tablet should be used only under the supervision of a qualified healthcare provider. It is not recommended during pregnancy, particularly in the second and third trimesters, due to the risk of fetal toxicity. Caution is advised in patients with kidney impairment, liver disease, or those receiving diuretics, as the risk of hypotension and electrolyte imbalance may be higher. If switching from another antihypertensive or initiating in volume-depleted patients, start under close supervision. Patients should avoid potassium-rich supplements or salt substitutes unless advised. Inform your doctor immediately if swelling, difficulty breathing, or severe dizziness occurs. Regular follow-up is essential for safe and effective use.
Store Perihype Tablet in a cool, dry place below 30°C. Protect it from moisture, direct sunlight, and heat. Keep the medication out of reach of children and pets. Do not use the tablet beyond its expiry date and store it in its original packaging.